Article

Trials to test efficacy of ocular implants

Lincoln, RI?Biotechnology firm Neurotech Pharmaceuticals Inc. has begun two phase II/III clinical trials with NT-501, the company's lead Encapsulated Cell Technology (ECT) product for the treatment of visual loss associated with retinitis pigmentosa.

Lincoln, RI-Biotechnology firm Neurotech Pharmaceuticals Inc. has begun two phase II/III clinical trials with NT-501, the company's lead Encapsulated Cell Technology (ECT) product for the treatment of visual loss associated with retinitis pigmentosa.

The trials are part of Neurotech's Retinal Neurotrophic Ocular Implant Research Studies; one will treat patients at an earlier stage of the disease, and the other at a later stage. Randomized, double-masked, sham-controlled trials are being conducted at 14 U.S. sites.

NT-501 is an intraocular polymer implant containing human retinal epithelial cells genetically modified to secrete Ciliary Neurotrophic Factor (CNTF). The implant is designed to release CNTF continuously directly into the back of the eye for sustained periods.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) From MIGS to gene therapy: Inder Paul Singh, MD, celebrates the past and future of glaucoma care
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
© 2025 MJH Life Sciences

All rights reserved.